Please sign in to follow a disease.
Scientists probe gut immune cells to unlock HIV's hiding spots
NCT ID NCT07656077
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how HIV-1 hides in immune cells in the gut of people on effective antiretroviral therapy. Researchers will collect blood and colon tissue from 30 HIV-positive volunteers and healthy controls during routine colonoscopies. The goal is to understand why these gut cells die and how they help the virus persist, which could lead to better treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
I - Inclusion criteria 1 - Group 1: People Living With HIV-1 * Age ≥ 18 years * Documented HIV-1 infection * Continuous suppressive antiretroviral therapy initiated during chronic infection for at least 12 months * Plasma HIV-1 RNA ≤ 50 copies/mL for at least 6 months under ART (one isolated blip ≤ 200 copies/mL allowed) * Blood CD4+ T-cell count ≥ 350 cells/mm³ * Clinically indicated colonoscopy independent of the research protocol * Affiliation with a social security system * Written informed consent obtained before any study-specific procedure 2- Group 2: HIV-Seronegative Controls * Age ≥ 18 years * HIV-seronegative status * Clinically indicated colonoscopy independent of the research protocol * Affiliation with a social security system * Written informed consent obtained before any study-specific procedure II - Exclusion Criteria 1. Group 1: People Living With HIV-1 * HIV-2 infection * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease * Platelet count \< 50 G/L or uncorrectable coagulation disorders contraindicating biopsies * Decompensated cirrhosis * History of lymphoma * Participation in an HIV vaccine or immunotherapy study * Pregnant or breastfeeding women * Participation in another clinical study with an ongoing exclusion period * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty 2. Group 2: HIV-Seronegative Controls * HIV-1 or HIV-2 infection * Refusal to undergo HIV serology testing * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease * Platelet count \< 50 G/L or uncorrectable coagulation disorders contraindicating biopsies * Decompensated cirrhosis * History of lymphoma * Pregnant or breastfeeding women * Participation in another clinical study with an ongoing exclusion period * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Antiretroviral therapy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug flush out hidden HIV?
- Can two antibodies and a cancer drug free people with HIV from daily pills?
- Can a phone call keep HIV-Positive mothers and babies on track?
- Do unsuppressed HIV infections fuel new cases in ethiopia?
- A simple idea to stop STIs: send treatment home with the patient
- Could a single shot replace daily HIV pills?